TY - JOUR
T1 - Visceral fat area and cardiometabolic risk
T2 - The Kardiovize study
AU - Polcrova, Anna
AU - Pavlovska, Iuliia
AU - Maranhao Neto, Geraldo A.
AU - Kunzova, Sarka
AU - Infante-Garcia, Maria M.
AU - Medina-Inojosa, Jose R.
AU - Lopez-Jimenez, Francisco
AU - Mechanick, Jeffrey I.
AU - Nieto-Martinez, Ramfis
AU - Stokin, Gorazd B.
AU - Pikhart, Hynek
AU - Gonzalez-Rivas, Juan P.
N1 - Funding Information:
The Kardiovize study was supported by the European Regional Development Fund ? Project FNUSAICRC [no. CZ.1.05/1.1.00/02.0123], by project no. LQ1605 from the National Program of Sustainability II (MEYS CR), by project ENOCH (no. CZ.02.1.01/0.0/0.0/16_019/0000868) and by a grant by the Ministry of Health of the Czech Republic [NT13434-4/2012]. This research was also supported from the European Union's Horizon 2020 research and innovation programme under grant agreement No 857487.
Publisher Copyright:
© 2021 Asia Oceania Association for the Study of Obesity
PY - 2021
Y1 - 2021
N2 - Background: Visceral fat is associated with adiposity-based complications. Bioimpedance measurement allows estimation of visceral fat area (VFA) in an easy manner. However, a validated cut-off value for VFA by bioimpedance associated with cardiometabolic risk is lacking in European population. Aim: To determine cut-off values of VFA measured via bioimpedance associated with cardiometabolic risk. Methods: Random cross-sectional Czech population-based sample of 25–64 years old subjects. Receiver Operating Characteristic (ROC) curves were used and the area under the curve (AUC), sensitivity, and specificity were calculated. The Cardiometabolic Disease Staging System (CMDS) was used to classify cardiometabolic risk: Stage 1 – 1 or 2 metabolic syndrome (MetS) components, without impaired fasting glucose (IFG); Stage 2 – MetS or IFG; Stage 3 – MetS with IFG; Stage 4 – type 2 diabetes and/or cardiovascular disease. Results: 2052 participants (54.5% females, median age 49 years) were included. Median VFA (inter-quartile range) were 82.2 cm2 (54.8) in men and 89.8 cm2 (55.6) in women. The best VFA cut-offs associated with Stage 1 in men and women were 71 cm2 (sensitivity = 0.654; specificity = 0.427) and 83 cm2 (sensitivity = 0.705; specificity = 0.556); Stage 2: 84 cm2 (sensitivity = 0.673; specificity = 0.551) and 98 cm2 (sensitivity = 0.702; specificity = 0.628); Stage 3: 90 cm2 (sensitivity = 0.886; specificity = 0.605) and 109 cm2 (sensitivity = 0.755; specificity = 0.704); Stage 4: 91 cm2 (sensitivity = 0.625; specificity = 0.611) and 81 cm2 (sensitivity = 0.695; specificity = 0.448), respectively. Conclusion: A cut-off value of VFA of 71 cm2 in men and 83 cm2 in women exhibited the earliest stage of cardiometabolic risk, and 90 cm2 in men and 109 cm2 in women showed the best performance to detect risk.
AB - Background: Visceral fat is associated with adiposity-based complications. Bioimpedance measurement allows estimation of visceral fat area (VFA) in an easy manner. However, a validated cut-off value for VFA by bioimpedance associated with cardiometabolic risk is lacking in European population. Aim: To determine cut-off values of VFA measured via bioimpedance associated with cardiometabolic risk. Methods: Random cross-sectional Czech population-based sample of 25–64 years old subjects. Receiver Operating Characteristic (ROC) curves were used and the area under the curve (AUC), sensitivity, and specificity were calculated. The Cardiometabolic Disease Staging System (CMDS) was used to classify cardiometabolic risk: Stage 1 – 1 or 2 metabolic syndrome (MetS) components, without impaired fasting glucose (IFG); Stage 2 – MetS or IFG; Stage 3 – MetS with IFG; Stage 4 – type 2 diabetes and/or cardiovascular disease. Results: 2052 participants (54.5% females, median age 49 years) were included. Median VFA (inter-quartile range) were 82.2 cm2 (54.8) in men and 89.8 cm2 (55.6) in women. The best VFA cut-offs associated with Stage 1 in men and women were 71 cm2 (sensitivity = 0.654; specificity = 0.427) and 83 cm2 (sensitivity = 0.705; specificity = 0.556); Stage 2: 84 cm2 (sensitivity = 0.673; specificity = 0.551) and 98 cm2 (sensitivity = 0.702; specificity = 0.628); Stage 3: 90 cm2 (sensitivity = 0.886; specificity = 0.605) and 109 cm2 (sensitivity = 0.755; specificity = 0.704); Stage 4: 91 cm2 (sensitivity = 0.625; specificity = 0.611) and 81 cm2 (sensitivity = 0.695; specificity = 0.448), respectively. Conclusion: A cut-off value of VFA of 71 cm2 in men and 83 cm2 in women exhibited the earliest stage of cardiometabolic risk, and 90 cm2 in men and 109 cm2 in women showed the best performance to detect risk.
KW - Cardiometabolic risk factors
KW - Intra-abdominal fat
KW - Race factors
UR - http://www.scopus.com/inward/record.url?scp=85102779539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102779539&partnerID=8YFLogxK
U2 - 10.1016/j.orcp.2021.03.005
DO - 10.1016/j.orcp.2021.03.005
M3 - Article
AN - SCOPUS:85102779539
JO - Obesity Research and Clinical Practice
JF - Obesity Research and Clinical Practice
SN - 1871-403X
ER -